A clinical case of the use of a new selective μ1-opioid analgesic Tafalgin in the treatment of chronic cancer pain
In the Russian Federation, tetrapeptide tyrosyl-D-arginyl-phenylalanyl-glycine amide (Tafalgin), a novel analgesic, selective agonist of 1-opioid receptors, was developed and approved in 2022. The article presents the first experience of the successful use of Tafalgin in treating chronic pain in a c...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IP Habib O.N.
2022-11-01
|
| Series: | Современная онкология |
| Subjects: | |
| Online Access: | https://modernonco.orscience.ru/1815-1434/article/viewFile/111868/pdf |